Skip to main content

Research Repository

Advanced Search

Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study

Hezzell, M J; Boswood, A; Lopez-Alvarez, J; Lotter, N S; Elliott, J

Authors

M J Hezzell

A Boswood

J Lopez-Alvarez

N S Lotter

J Elliott



Abstract

Spironolactone improves outcome in dogs with advanced myxomatous mitral valve disease (MMVD). Its efficacy in preclinical MMVD is unknown. The hypothesis was the administration of spironolactone to dogs with compensated MMVD demonstrating risk factors for poorer prognosis will decrease the rate of disease progression. The aim was to provide pilot data to evaluate preliminary effects and sample size calculation for a definitive clinical trial.

Citation

Hezzell, M. J., Boswood, A., Lopez-Alvarez, J., Lotter, N. S., & Elliott, J. (2017). Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study. Journal of Veterinary Cardiology, 19(4), 325-328. https://doi.org/10.1016/j.jvc.2017.06.001

Journal Article Type Article
Acceptance Date Jun 15, 2017
Publication Date Jul 19, 2017
Deposit Date Aug 22, 2017
Publicly Available Date Aug 1, 2018
Journal Journal of Veterinary Cardiology
Print ISSN 1760-2734
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 19
Issue 4
Pages 325-328
DOI https://doi.org/10.1016/j.jvc.2017.06.001
Public URL https://rvc-repository.worktribe.com/output/1391211

Files






You might also like



Downloadable Citations